These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


722 related items for PubMed ID: 26293803

  • 1. Bedaquiline and delamanid in tuberculosis.
    Esposito S, Bianchini S, Blasi F.
    Expert Opin Pharmacother; 2015; 16(15):2319-30. PubMed ID: 26293803
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D, Dass R, Hettle R.
    BMC Health Serv Res; 2017 Mar 08; 17(1):182. PubMed ID: 28270207
    [Abstract] [Full Text] [Related]

  • 3. Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations.
    Hu M, Zheng C, Gao F.
    Drug Des Devel Ther; 2016 Mar 08; 10():3983-3994. PubMed ID: 27994440
    [Abstract] [Full Text] [Related]

  • 4. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
    Kwon YS, Jeong BH, Koh WJ.
    Expert Opin Pharmacother; 2015 Feb 08; 16(2):253-61. PubMed ID: 25327169
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB.
    Millard J, Rimmer S, Nimmo C, O'Donnell M.
    Emerg Infect Dis; 2023 May 08; 29(5):1081-1084. PubMed ID: 37081529
    [Abstract] [Full Text] [Related]

  • 6. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
    Polsfuss S, Hofmann-Thiel S, Merker M, Krieger D, Niemann S, Rüssmann H, Schönfeld N, Hoffmann H, Kranzer K.
    Clin Infect Dis; 2019 Sep 13; 69(7):1229-1231. PubMed ID: 30933266
    [Abstract] [Full Text] [Related]

  • 7. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
    Pontali E, Visca D, Centis R, D'Ambrosio L, Spanevello A, Migliori GB.
    Curr Opin Pulm Med; 2018 May 13; 24(3):244-252. PubMed ID: 29470252
    [Abstract] [Full Text] [Related]

  • 8. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
    Khan U, Huerga H, Khan AJ, Mitnick CD, Hewison C, Varaine F, Bastard M, Rich M, Franke MF, Atwood S, Khan PY, Seung KJ.
    BMC Infect Dis; 2019 Aug 20; 19(1):733. PubMed ID: 31429722
    [Abstract] [Full Text] [Related]

  • 9. Profile of delamanid for the treatment of multidrug-resistant tuberculosis.
    Szumowski JD, Lynch JB.
    Drug Des Devel Ther; 2015 Aug 20; 9():677-82. PubMed ID: 25678771
    [Abstract] [Full Text] [Related]

  • 10. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
    Maryandyshev A, Pontali E, Tiberi S, Akkerman O, Ganatra S, Sadutshang TD, Alffenaar JW, Amale R, Mullerpattan J, Topgyal S, Udwadia ZF, Centis R, D'Ambrosio L, Sotgiu G, Migliori GB.
    Emerg Infect Dis; 2017 Oct 20; 23(10):1718-21. PubMed ID: 28758888
    [Abstract] [Full Text] [Related]

  • 11. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS, Kim KJ, Choi H, Lee SH.
    Ann Lab Med; 2018 Nov 20; 38(6):563-568. PubMed ID: 30027700
    [Abstract] [Full Text] [Related]

  • 12. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y, Matsumoto M, Ishida H, Ohguro K, Yoshitake M, Gupta R, Geiter L, Hafkin J.
    Tuberculosis (Edinb); 2018 Jul 20; 111():20-30. PubMed ID: 30029909
    [Abstract] [Full Text] [Related]

  • 13. Management of drug resistantTB in patients with HIV co-infection.
    Pontali E, Sotgiu G, Centis R, D'Ambrosio L, Spanevello A, Migliori GB.
    Expert Opin Pharmacother; 2015 Jul 20; 16(18):2737-50. PubMed ID: 26478945
    [Abstract] [Full Text] [Related]

  • 14. Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis.
    Mikiashvili L, Kempker RR, Chakhaia TS, Bablishvili N, Avaliani Z, Lomtadze N, Schechter MC, Kipiani M.
    Clin Infect Dis; 2024 Apr 10; 78(4):1043-1052. PubMed ID: 37962987
    [Abstract] [Full Text] [Related]

  • 15. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
    Migliori GB, Pontali E, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Tadolini M, Esposito S.
    Int J Mol Sci; 2017 Feb 07; 18(2):. PubMed ID: 28178199
    [Abstract] [Full Text] [Related]

  • 16. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Dooley KE, Rosenkranz SL, Conradie F, Moran L, Hafner R, von Groote-Bidlingmaier F, Lama JR, Shenje J, De Los Rios J, Comins K, Morganroth J, Diacon AH, Cramer YS, Donahue K, Maartens G, AIDS Clinical Trials Group (ACTG) A5343 DELIBERATE Study Team.
    Lancet Infect Dis; 2021 Jul 07; 21(7):975-983. PubMed ID: 33587897
    [Abstract] [Full Text] [Related]

  • 17. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, Khachatryan N, De Avezedo V, Egazaryan L, Shroufi A, Kalon S, Cox H, Furin J, Isaakidis P.
    Lancet Infect Dis; 2018 May 07; 18(5):536-544. PubMed ID: 29452942
    [Abstract] [Full Text] [Related]

  • 18. Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis.
    Thakare R, Soni I, Dasgupta A, Chopra S.
    Drugs Today (Barc); 2015 Feb 07; 51(2):117-23. PubMed ID: 25756067
    [Abstract] [Full Text] [Related]

  • 19. Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician's perspective.
    Guglielmetti L, Chiesi S, Eimer J, Dominguez J, Masini T, Varaine F, Veziris N, Ader F, Robert J.
    Future Microbiol; 2020 Jun 07; 15():779-799. PubMed ID: 32700565
    [Abstract] [Full Text] [Related]

  • 20. Global Introduction of New Multidrug-Resistant Tuberculosis Drugs-Balancing Regulation with Urgent Patient Needs.
    Sullivan T, Ben Amor Y.
    Emerg Infect Dis; 2016 Mar 07; 22(3):. PubMed ID: 26889711
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 37.